Defining and treating high-risk multiple myeloma

被引：56

作者：

Usmani, S. Z. ^{[1
]}

Rodriguez-Otero, P. ^{[2
]}

Bhutani, M. ^{[1
]}

Mateos, M-V ^{[3
]}

Miguel, J. S. ^{[2
]}

机构：

[1] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol Blood Disorders & Bone Marrow, Charlotte, NC 28204 USA

[2] Univ Navarra Clin, Dept Hematol, CIMA, IDISNA, Navarra, Spain

[3] Univ Hosp Salamanca, IBSAL, Dept Hematol, Salamanca, Spain

来源：

LEUKEMIA | 2015年 / 29卷 / 11期

关键词：

STEM-CELL TRANSPLANTATION; SINGLE-AGENT CARFILZOMIB; GENETIC ABNORMALITIES; INTERGROUPE FRANCOPHONE; RANDOMIZED PHASE-3; PROGNOSTIC-FACTOR; INITIAL THERAPY; STAGING SYSTEM; SURVIVAL; IMPACT;

D O I：

10.1038/leu.2015.209

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) is more recently being recognized as a heterogeneous group of disease with variability in outcomes based on specific clinical and biologic predictors. MM patients can be broadly categorized into standard, intermediate and high risk for disease relapse, morbidity and mortality. The high-risk features include patient-specific factors such as old age, poor performance status and comorbidities; clinical features such as primary plasma cell leukemia and extramedullary disease; disease-specific biologic features such as deletion 17p, t(4;14) and high-risk gene expression profiling signatures. The current paper reviews the available data on best therapeutic approaches for high-risk MM.

引用

页码：2119 / 2125

页数：7

共 62 条

[11] A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial [J].

Boyd, K. D. ;

Ross, F. M. ;

Chiecchio, L. ;

Dagrada, G. P. ;

Konn, Z. J. ;

Tapper, W. J. ;

Walker, B. A. ;

Wardell, C. P. ;

Gregory, W. M. ;

Szubert, A. J. ;

Bell, S. E. ;

Child, J. A. ;

Jackson, G. H. ;

Davies, F. E. ;

Morgan, G. J. .

LEUKEMIA, 2012, 26 (02) :349-355

[12] Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials [J].

Bringhen, Sara ;

Victoria Mateos, Maria ;

Zweegman, Sonja ;

Larocca, Alessandra ;

Falcone, Antonietta Pia ;

Oriol, Albert ;

Rossi, Davide ;

Cavalli, Maide ;

Wijermans, Pierre ;

Ria, Roberto ;

Offidani, Massimo ;

Jose Lahuerta, Juan ;

Liberati, Anna Marina ;

Mina, Roberto ;

Callea, Vincenzo ;

Schaafsma, Martijn ;

Cerrato, Chiara ;

Marasca, Roberto ;

Franceschini, Luca ;

Evangelista, Andrea ;

Teruel, Ana-Isabel ;

van der Holt, Bronno ;

Montefusco, Vittorio ;

Ciccone, Giovannino ;

Boccadoro, Mario ;

San Miguel, Jesus ;

Sonneveld, Pieter ;

Palumbo, Antonio .

HAEMATOLOGICA, 2013, 98 (06) :980-987

[13] Impact of Bortezomib Incorporated Into Autotransplantation On Outcomes of Myeloma Patients with High-Risk Cytogenetics: An Integrated Analysis of 1894 Patients Enrolled in Four European Phase 3 Studies [J].

Cavo, Michele ;

Sonneveld, Pieter ;

Moreau, Philippe ;

Blade, Joan ;

Goldschmidt, Hartmut ;

San Miguel, Jesus F. ;

Attal, Michel ;

Avet-Loiseau, Herve ;

Blau, Wolgang Igor ;

Facon, Thierry ;

Gutierrez, Norma ;

Harousseau, Jean-Luc ;

van der Holt, Bronno ;

Jose Lahuerta, Juan ;

Lokhorst, Henk ;

Marit, Gerald ;

Luisa Martin, Maria ;

Marzocchi, Giulia ;

Palumbo, Antonio ;

Patriarca, Francesca ;

Petrucci, Maria Teresa ;

Rosinol, Laura ;

Salwender, Hans ;

Terragna, Carolina .

BLOOD, 2012, 120 (21)

[14] IMWG consensus on risk stratification in multiple myeloma [J].

Chng, W. J. ;

Dispenzieri, A. ;

Chim, C-S ;

Fonseca, R. ;

Goldschmidt, H. ;

Lentzsch, S. ;

Munshi, N. ;

Palumbo, A. ;

Miguel, J. S. ;

Sonneveld, P. ;

Cavo, M. ;

Usmani, S. ;

Durie, B. G. M. ;

Avet-Loiseau, H. .

LEUKEMIA, 2014, 28 (02) :269-277

[15] Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:: A study of the intergroupe francophone du myelome [J].

Decaux, Olivier ;

Lode, Laurence ;

Magrangeas, Florence ;

Charbonnel, Catherine ;

Gouraud, Wilfried ;

Jezequel, Pascal ;

Attal, Michel ;

Harousseau, Jean-Luc ;

Moreau, Philippe ;

Bataille, Regis ;

Campion, Loic ;

Avert-Loiseau, Herve ;

Minvielle, Stephane .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4798-4805

[16]

Dimopoulos MA, 2013, BLOOD, V122

[17]

DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO

[18]

2-U

[19] Clinical and biologic implications of recurrent genomic aberrations in myeloma [J].

Fonseca, R ;

Blood, E ;

Rue, M ;

Harrington, D ;

Oken, MM ;

Kyle, RA ;

Dewald, GW ;

Van Ness, B ;

Van Wier, SA ;

Henderson, KJ ;

Bailey, RJ ;

Greipp, PR .

BLOOD, 2003, 101 (11) :4569-4575

[20] International Myeloma Working Group molecular classification of multiple myeloma: spotlight review [J].

Fonseca, R. ;

Bergsagel, P. L. ;

Drach, J. ;

Shaughnessy, J. ;

Gutierrez, N. ;

Stewart, A. K. ;

Morgan, G. ;

Van Ness, B. ;

Chesi, M. ;

Minvielle, S. ;

Neri, A. ;

Barlogie, B. ;

Kuehl, W. M. ;

Liebisch, P. ;

Davies, F. ;

Chen-Kiang, S. ;

Durie, B. G. M. ;

Carrasco, R. ;

Sezer, Orhan ;

Reiman, Tony ;

Pilarski, Linda ;

Avet-Loiseau, H. .

LEUKEMIA, 2009, 23 (12) :2210-2221

← 1 2 3 4 5 6 7 →